

Buy EUR 6.40 Price EUR 3.83 Upside 67.1 %	Value Indicators: EUR DCF: 6.40	Share data: Bloomberg: FPH GR Reuters: FPHG ISIN: DE000FPH9000	Description: Manufacturer of franking machines and provider of mail services.
	Market Snapshot: EUR m Market cap: 59.2 No. of shares (m): 15.5 EV: 91.8 Freefloat MC: 46.6 Ø Trad. Vol. (30d): 36.75 th	Shareholders: Freefloat 78.7 % Quaero Capital 5.2 % Active Ownership Fund 9.5 % Obotritia Capital 6.6 %	Risk Profile (WRe): 2018e Beta: 1.6 Price / Book: 1.9 x Equity Ratio: 19 % Net Fin. Debt / EBITDA: 0.8 x Net Debt / EBITDA: 1.6 x

Jump is coming in Q4

Stated Figures Q3/2018:

in EUR m	Q3/18	Q3/18e	Q3/17	yoy	9M/18	9M/17	yoy
Sales	49.5	50.5	49.4	0.1%	154.3	153.9	0.3%
EBITDA	4.2	3.0	7.0	-39.0%	17.0	19.7	-13.5%
margin	8.6%	14.8%	14.1%		11.0%	12.8%	
EPS in EUR	0.01	-0.05	0.08	-87.5%	0.20	0.21	-4.8%

Comment on Figures:

- Francotyp Postalia AG presented its Q3/9M 2018 figures on Nov. 15.
- While revenues were marginally below expectations, earnings significantly exceeded the forecasts (WRe). This was again due to the fact that the company only spent EUR 1.4m of the EUR 6-8m budgeted for the Jump programme for the full year. Significantly more had been expected (WRe).

The core of the reported figures are two aspects: Firstly, there are signs that the EBIT forecast (WRe) before expenses for the Jump programme will be achieved. In the first nine months, EBIT (excl. Jump) reached EUR 5.6m. The expectation for the full year is EUR 8m (WRe, without Jump), which should just be reached.

Secondly, at EUR 1.4m, expenses for the Jump programme in the first nine months are far below what the targeted figure of EUR 6-8m for 2018 would have led us to expect. This is due to the fact that significant expenses of the Jump programme are provisions for personnel measures. These provisions are not expected to be recognized until Q4. A loss (EBIT of EUR -2m to EUR -3m WRe) is therefore expected for Q4. However, the slightly different distribution of expenses for the Jump programme compared to the expectation (WRe) has no influence on the forecasts or the assessment.

The core business with franking machines should once again be highlighted in the quarterly figures, as it rose by 4.1% to EUR 98.8m in the first nine months adjusted for currency effects. It gained market share in all markets and in comparison to all important competitors. The reason for this is that franking machines are no longer a focus of the growth strategy for major peers Neopost and Pitney Bowes. Francotyp is successfully closing this gap.

Therefore, there is no need to adjust the forecasts and the assessment of the share. Since the Jump programme is expected to generate annual savings of around EUR 6m from 2020 onwards and a return to normalised earnings levels (cf. EPS 2016: 0.36) already indicates a significant valuation reserve, the share remains very attractively priced.

Francotyp shares continue to be rated as Buy with a price target of EUR 6.40.




Rel. Performance vs CDAX:	
1 month:	9.2 %
6 months:	30.2 %
Year to date:	-4.8 %
Trailing 12 months:	-3.9 %

Company events:	


FY End: 31.12. in EUR m	CAGR (17-20e)	2014	2015	2016	2017	2018e	2019e	2020e
Sales	4.4 %	170.3	191.1	203.0	206.3	213.2	223.9	235.1
Change Sales yoy		0.8 %	12.2 %	6.2 %	1.7 %	3.3 %	5.0 %	5.0 %
Gross profit margin		61.3 %	60.4 %	58.1 %	55.6 %	56.1 %	57.3 %	57.1 %
EBITDA	9.3 %	23.1	26.8	27.2	26.3	20.0	31.0	34.3
Margin		13.6 %	14.0 %	13.4 %	12.8 %	9.4 %	13.8 %	14.6 %
EBIT	31.1 %	9.8	9.0	9.7	7.3	2.0	13.0	16.3
Margin		5.8 %	4.7 %	4.8 %	3.5 %	0.9 %	5.8 %	7.0 %
Net income	34.3 %	5.1	3.5	5.9	4.6	1.7	9.0	11.3
EPS	34.1 %	0.32	0.22	0.36	0.29	0.11	0.56	0.70
EPS adj.	34.1 %	0.32	0.22	0.36	0.29	0.11	0.56	0.70
DPS	20.5 %	0.16	0.16	0.16	0.16	0.00	0.22	0.28
Dividend Yield		3.6 %	3.7 %	3.8 %	3.1 %	n.a.	5.8 %	7.3 %
FCF / Market cap		-0.36	-0.10	0.28	0.35	-0.25	0.18	0.32
		-8.3 %	-2.2 %	0.2 %	6.8 %	-6.5 %	4.7 %	8.4 %
EV / Sales		0.6 x	0.5 x	0.5 x	0.5 x	0.4 x	0.4 x	0.4 x
EV / EBITDA		4.4 x	3.9 x	3.6 x	4.2 x	4.7 x	3.0 x	2.7 x
EV / EBIT		10.5 x	11.5 x	9.9 x	15.1 x	47.1 x	7.1 x	5.6 x
P / E		13.7 x	19.8 x	11.7 x	17.9 x	34.8 x	6.8 x	5.5 x
P / E adj.		13.7 x	19.8 x	11.7 x	17.9 x	34.8 x	6.8 x	5.5 x
FCF Potential Yield		3.5 %	6.1 %	12.0 %	11.2 %	8.3 %	16.4 %	19.0 %
Net Debt		31.6	32.9	28.4	25.2	32.6	30.6	29.5
ROCE (NOPAT)		11.0 %	6.8 %	9.5 %	7.8 %	2.5 %	12.9 %	14.8 %
Guidance:	n.a.							

Sales development in EUR m




Source: Warburg Research

Recurring revenue proportion 2018e; in %



Source: Warburg Research

EBIT development in EUR m



Source: Warburg Research


Company Background

- Francotyp Postalia Holding AG, headquartered in Berlin, is a globally-active supplier of products and services for the postal market.
- The company was formed in 1983 with the merger of Francotyp (founded 1923) and Postalia (founded 1938) and has thus more than 80 years of experience in the postal market.
- In the course of the liberalisation of the postal market, the FP group transformed itself from a producer of franking machines to a solutions provider for mail management and processing.
- Franking and inserting machines are still the core business activity.
- With new services like collection, sorting and bundling of outgoing mail as well as electronic hybrid mail solutions, the company expanded its product portfolio.

Competitive Quality


- Focusing on customers with low to medium postal needs, Francotyp Postalia caters for two stable segments in the generally difficult market for franking machines.
- The 45% market share in the German market for franking machines demonstrates its reputation as the market leader in Germany based on the following distinguishing characteristics:
 - established customer relationships and 80 years of experience in the German market with knowledge of customer demands and an efficient service network with rapid reaction times.
- The high proportion (about three-quarters) of recurring revenues as a share of total revenue underlines the successful transformation of the competitive quality into a high company quality.
- For new market entrants, Francotyp Postalia's existing customer base is an unachievable target and the franking machines niche is unattractive.

EBT development in EUR m




Source: Warburg Research

Net debt in EURm



Source: Warburg Research

Net income development in EUR m



Source: Warburg Research

DCF model

Figures in EUR m	Detailed forecast period			Transitional period										Term. Value
	2018e	2019e	2020e	2021e	2022e	2023e	2024e	2025e	2026e	2027e	2028e	2029e	2030e	
Sales	213.2	223.9	235.1	241.0	247.0	253.2	259.5	266.0	272.6	279.5	286.4	293.6	300.9	1.0 %
Sales change	3.3 %	5.0 %	5.0 %	2.5 %	2.5 %	2.5 %	2.5 %	2.5 %	2.5 %	2.5 %	2.5 %	2.5 %	2.5 %	
EBIT	2.0	13.0	16.3	16.9	17.3	17.7	18.2	18.6	19.1	19.6	20.1	20.6	21.1	7.0 %
EBIT-margin	0.9 %	5.8 %	7.0 %	7.0 %	7.0 %	7.0 %	7.0 %	7.0 %	7.0 %	7.0 %	7.0 %	7.0 %	7.0 %	
Tax rate (EBT)	22.6 %	32.0 %	32.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	30.0 %	14
NOPAT	1.6	8.8	11.1	11.8	12.1	12.4	12.7	13.0	13.4	13.7	14.0	14.4	14.7	
Depreciation	18.0	18.0	18.0	21.7	22.2	22.8	23.4	23.9	24.5	25.2	25.8	26.4	27.1	74
in % of Sales	8.4 %	8.0 %	7.7 %	9.0 %	9.0 %	9.0 %	9.0 %	9.0 %	9.0 %	9.0 %	9.0 %	9.0 %	9.0 %	
Changes in provisions	0.8	0.9	0.9	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	59.76 %
Change in Liquidity from														
- Working Capital	0.6	0.9	1.0	9.5	1.2	1.3	1.3	1.4	1.4	1.5	1.5	1.6	1.6	42.52 %
- Capex	26.0	26.0	26.0	24.1	24.7	25.3	26.0	23.9	24.5	25.2	25.8	26.4	27.1	
Capex in % of Sales	12.2 %	11.6 %	11.1 %	10.0 %	10.0 %	10.0 %	10.0 %	9.0 %	9.0 %	9.0 %	9.0 %	9.0 %	9.0 %	-2.28 %
Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Free Cash Flow (WACC Model)	-6.2	0.8	3.0	0.7	8.4	8.6	8.8	11.7	11.9	12.2	12.5	12.8	13.1	42.52 %
PV of FCF	-6.0	0.7	2.5	0.6	6.0	5.7	5.4	6.6	6.2	5.9	5.6	5.3	5.0	
share of PVs	-2.28 %			42.52 %										59.76 %

Model parameter

Derivation of WACC:		Derivation of Beta:	
Debt ratio	25.00 %	Financial Strength	1.80
Cost of debt (after tax)	2.1 %	Liquidity (share)	1.30
Market return	7.00 %	Cyclicality	1.50
Risk free rate	1.50 %	Transparency	1.80
		Others	1.40
WACC	8.09 %	Beta	1.56

Valuation (m)

Present values 2030e	50		
Terminal Value	74		
Financial liabilities	44		
Pension liabilities	17		
Hybrid capital	0		
Minority interest	0		
Market val. of investments	0		
Liquidity	36	No. of shares (m)	15.5
Equity Value	99	Value per share (EUR)	6.40

Sensitivity Value per Share (EUR)

		Terminal Growth									Delta EBIT-margin						
Beta	WACC	0.25 %	0.50 %	0.75 %	1.00 %	1.25 %	1.50 %	1.75 %	Beta	WACC	-1.5 pp	-1.0 pp	-0.5 pp	+0.0 pp	+0.5 pp	+1.0 pp	+1.5 pp
1.80	9.1 %	4.80	4.90	5.01	5.12	5.24	5.36	5.50	1.80	9.1 %	2.95	3.67	4.40	5.12	5.84	6.56	7.28
1.68	8.6 %	5.34	5.46	5.58	5.72	5.86	6.01	6.18	1.68	8.6 %	3.41	4.18	4.95	5.72	6.48	7.25	8.02
1.62	8.3 %	5.63	5.76	5.90	6.05	6.20	6.37	6.56	1.62	8.3 %	3.67	4.46	5.25	6.05	6.84	7.63	8.43
1.56	8.1 %	5.95	6.09	6.24	6.40	6.58	6.76	6.97	1.56	8.1 %	3.94	4.76	5.58	6.40	7.22	8.04	8.86
1.50	7.8 %	6.28	6.44	6.61	6.78	6.98	7.19	7.41	1.50	7.8 %	4.23	5.08	5.93	6.78	7.63	8.48	9.33
1.44	7.6 %	6.64	6.81	7.00	7.20	7.41	7.64	7.89	1.44	7.6 %	4.55	5.43	6.32	7.20	8.08	8.96	9.84
1.32	7.1 %	7.45	7.66	7.88	8.13	8.40	8.69	9.00	1.32	7.1 %	5.27	6.22	7.18	8.13	9.08	10.03	10.99

- Francotyp generates high steady cash flows in a normal business year.
- For 2013 and beyond, cash flows are characterised by high investments in the installed base for years
- The company's cash flow strength will only be revealed in the long term

Valuation	2014	2015	2016	2017	2018e	2019e	2020e
Price / Book	2.5 x	2.1 x	1.9 x	2.6 x	1.9 x	1.5 x	1.3 x
Book value per share ex intangibles	-0.26	0.04	0.07	-0.13	-0.62	-0.49	-0.44
EV / Sales	0.6 x	0.5 x	0.5 x	0.5 x	0.4 x	0.4 x	0.4 x
EV / EBITDA	4.4 x	3.9 x	3.6 x	4.2 x	4.7 x	3.0 x	2.7 x
EV / EBIT	10.5 x	11.5 x	9.9 x	15.1 x	47.1 x	7.1 x	5.6 x
EV / EBIT adj.*	10.5 x	11.5 x	9.9 x	15.1 x	47.1 x	7.1 x	5.6 x
P / FCF	n.a.	n.a.	426.4 x	14.7 x	n.a.	21.3 x	11.9 x
P / E	13.7 x	19.8 x	11.7 x	17.9 x	34.8 x	6.8 x	5.5 x
P / E adj.*	13.7 x	19.8 x	11.7 x	17.9 x	34.8 x	6.8 x	5.5 x
Dividend Yield	3.6 %	3.7 %	3.8 %	3.1 %	n.a.	5.8 %	7.3 %
FCF Potential Yield (on market EV)	3.5 %	6.1 %	12.0 %	11.2 %	8.3 %	16.4 %	19.0 %
*Adjustments made for: -							

Consolidated profit & loss

In EUR m	2014	2015	2016	2017	2018e	2019e	2020e
Sales	170.3	191.1	203.0	206.3	213.2	223.9	235.1
Change Sales yoy	0.8 %	12.2 %	6.2 %	1.7 %	3.3 %	5.0 %	5.0 %
Increase / decrease in inventory	0.6	-0.1	0.2	0.5	0.0	0.0	0.0
Own work capitalised	15.5	15.8	11.4	10.8	10.8	10.8	10.8
Total Sales	186.4	206.7	214.5	217.7	224.1	234.7	245.9
Material expenses	82.0	91.3	96.5	102.9	104.5	106.4	111.7
Gross profit	104.3	115.4	118.0	114.8	119.6	128.4	134.3
Gross profit margin	61.3 %	60.4 %	58.1 %	55.6 %	56.1 %	57.3 %	57.1 %
Personnel expenses	53.5	57.4	57.4	59.2	64.0	61.6	63.5
Other operating income	2.4	4.3	3.8	4.8	4.3	4.5	4.7
Other operating expenses	30.1	35.6	37.1	34.1	39.9	40.3	41.1
Unfrequent items	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	23.1	26.8	27.2	26.3	20.0	31.0	34.3
Margin	13.6 %	14.0 %	13.4 %	12.8 %	9.4 %	13.8 %	14.6 %
Depreciation of fixed assets	8.6	17.8	17.5	19.1	18.0	18.0	18.0
EBITA	14.5	9.0	9.7	7.3	2.0	13.0	16.3
Amortisation of intangible assets	4.6	0.0	0.0	0.0	0.0	0.0	0.0
Goodwill amortisation	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	9.8	9.0	9.7	7.3	2.0	13.0	16.3
Margin	5.8 %	4.7 %	4.8 %	3.5 %	0.9 %	5.8 %	7.0 %
EBIT adj.	9.8	9.0	9.7	7.3	2.0	13.0	16.3
Interest income	0.5	0.7	1.3	2.1	0.8	0.8	0.8
Interest expenses	2.6	2.2	1.6	1.9	0.6	0.6	0.6
Other financial income (loss)	0.7	0.2	0.1	-0.4	0.0	0.0	0.0
EBT	8.4	7.7	9.6	7.1	2.2	13.2	16.5
Margin	4.9 %	4.0 %	4.7 %	3.4 %	1.0 %	5.9 %	7.0 %
Total taxes	3.2	3.9	3.4	2.4	0.5	4.2	5.3
Net income from continuing operations	5.2	3.7	6.2	4.6	1.7	9.0	11.3
Income from discontinued operations (net of tax)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income before minorities	5.2	3.7	6.2	4.6	1.7	9.0	11.3
Minority interest	0.1	0.2	0.3	0.0	0.0	0.0	0.0
Net income	5.1	3.5	5.9	4.6	1.7	9.0	11.3
Margin	3.0 %	1.9 %	2.9 %	2.3 %	0.8 %	4.0 %	4.8 %
Number of shares, average	16.2	16.2	16.2	16.2	16.2	16.2	16.2
EPS	0.32	0.22	0.36	0.29	0.11	0.56	0.70
EPS adj.	0.32	0.22	0.36	0.29	0.11	0.56	0.70

*Adjustments made for:


Guidance: n.a.

Financial Ratios

	2014	2015	2016	2017	2018e	2019e	2020e
Total Operating Costs / Sales	95.9 %	94.2 %	92.3 %	92.8 %	95.7 %	91.0 %	90.0 %
Operating Leverage	-6.5 x	-0.7 x	1.3 x	-15.3 x	-21.6 x	109.4 x	5.2 x
EBITDA / Interest expenses	8.8 x	11.9 x	17.4 x	13.8 x	33.3 x	51.7 x	57.2 x
Tax rate (EBT)	38.0 %	51.3 %	35.5 %	34.3 %	22.6 %	32.0 %	32.0 %
Dividend Payout Ratio	49.6 %	69.4 %	41.7 %	55.6 %	0.0 %	40.4 %	40.2 %
Sales per Employee	149,276	164,180	170,997	170,431	172,677	177,756	182,984


Sales, EBITDA

in EUR m




Operating Performance

in %



Performance per Share



Source: Warburg Research

Source: Warburg Research

Source: Warburg Research


Consolidated balance sheet

In EUR m	2014	2015	2016	2017	2018e	2019e	2020e
Assets							
Goodwill and other intangible assets	32.9	33.0	34.9	35.1	42.1	49.1	56.1
thereof other intangible assets	23.8	24.5	26.4	26.7	33.7	40.7	47.7
thereof Goodwill	9.1	8.5	8.5	8.5	8.5	8.5	8.5
Property, plant and equipment	37.0	42.0	39.3	31.8	32.8	33.8	34.8
Financial assets	3.0	6.0	9.7	11.6	11.6	11.6	11.6
Other long-term assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Fixed assets	73.0	81.0	83.9	78.5	86.5	94.5	102.5
Inventories	10.0	11.7	11.2	10.6	11.0	11.5	12.1
Accounts receivable	17.3	16.9	19.0	18.7	19.3	20.2	21.3
Liquid assets	17.2	18.9	27.1	34.9	25.1	26.0	26.0
Other short-term assets	24.6	27.6	26.2	27.1	26.5	26.5	26.5
Current assets	69.2	75.1	83.4	91.3	81.9	84.3	85.9
Total Assets	142.1	156.2	167.3	169.8	168.4	178.8	188.4
Liabilities and shareholders' equity							
Subscribed capital	16.2	16.2	16.2	16.3	16.3	16.3	16.3
Capital reserve	35.0	34.9	34.6	34.8	34.8	34.8	34.8
Retained earnings	5.1	3.5	0.0	0.0	-20.7	-18.9	-13.2
Other equity components	-27.6	-20.9	-14.9	-18.1	1.7	9.0	11.3
Shareholders' equity	28.7	33.7	35.9	33.0	32.1	41.2	49.1
Minority interest	1.4	1.5	0.0	0.0	0.0	0.0	0.0
Total equity	30.1	35.2	35.9	33.0	32.1	41.2	49.1
Provisions	22.9	22.3	18.0	17.7	18.5	19.4	20.3
thereof provisions for pensions and similar obligations	17.4	15.5	17.1	16.5	17.4	18.2	19.1
Financial liabilities (total)	31.4	36.3	38.4	43.6	40.4	38.4	36.4
thereof short-term financial liabilities	5.5	4.6	0.9	0.4	0.4	0.4	0.4
Accounts payable	9.5	9.9	10.6	11.2	11.6	12.2	12.8
Other liabilities	48.3	52.5	64.3	64.4	65.8	67.7	69.8
Liabilities	112.1	120.9	131.4	136.8	136.3	137.7	139.3
Total liabilities and shareholders' equity	142.1	156.2	167.3	169.8	168.4	178.8	188.4


Financial Ratios

	2014	2015	2016	2017	2018e	2019e	2020e
Efficiency of Capital Employment							
Operating Assets Turnover	3.1 x	3.1 x	3.4 x	4.1 x	4.1 x	4.2 x	4.2 x
Capital Employed Turnover	2.8 x	2.8 x	3.2 x	3.5 x	3.3 x	3.1 x	3.0 x
ROA	7.0 %	4.4 %	7.0 %	5.9 %	2.0 %	9.5 %	11.0 %
Return on Capital							
ROCE (NOPAT)	11.0 %	6.8 %	9.5 %	7.8 %	2.5 %	12.9 %	14.8 %
ROE	18.9 %	11.4 %	16.8 %	13.5 %	5.3 %	24.5 %	24.9 %
Adj. ROE	18.9 %	11.4 %	16.8 %	13.5 %	5.3 %	24.5 %	24.9 %
Balance sheet quality							
Net Debt	31.6	32.9	28.4	25.2	32.6	30.6	29.5
Net Financial Debt	14.2	17.4	11.4	8.6	15.3	12.4	10.4
Net Gearing	105.1 %	93.3 %	79.1 %	76.3 %	101.7 %	74.3 %	60.1 %
Net Fin. Debt / EBITDA	61.6 %	65.0 %	41.8 %	32.8 %	76.3 %	39.9 %	30.2 %
Book Value / Share	1.8	2.1	2.2	2.0	2.0	2.5	3.0
Book value per share ex intangibles	-0.3	0.0	0.1	-0.1	-0.6	-0.5	-0.4


ROCE Development



Net debt in EUR m



Book Value per Share in EUR



Source: Warburg Research

Source: Warburg Research

Source: Warburg Research

Consolidated cash flow statement


In EUR m	2014	2015	2016	2017	2018e	2019e	2020e
Net income	5.1	3.5	5.9	4.6	1.7	9.0	11.3
Depreciation of fixed assets	8.6	17.8	17.5	19.1	18.0	18.0	18.0
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	4.6	0.0	0.0	0.0	0.0	0.0	0.0
Increase/decrease in long-term provisions	3.3	-1.9	1.6	-0.5	0.8	0.9	0.9
Other non-cash income and expenses	2.0	2.0	0.0	0.0	2.0	2.0	2.0
Cash Flow before NWC change	23.6	21.4	24.9	23.2	22.5	29.8	32.2
Increase / decrease in inventory	-1.2	-1.7	0.5	0.6	-0.4	-0.5	-0.6
Increase / decrease in accounts receivable	-0.3	0.4	-2.0	0.3	-0.6	-1.0	-1.0
Increase / decrease in accounts payable	2.0	0.4	0.8	0.6	0.4	0.6	0.6
Increase / decrease in other working capital positions	-6.7	-2.0	-2.0	-3.5	0.0	0.0	0.0
Increase / decrease in working capital (total)	-6.2	-2.9	-2.8	-2.0	-0.6	-0.9	-1.0
Net cash provided by operating activities [1]	17.5	18.6	22.2	21.2	22.0	28.9	31.2
Investments in intangible assets	-5.1	-5.8	-6.7	-6.9	-7.0	-7.0	-7.0
Investments in property, plant and equipment	-18.3	-14.3	-15.3	-8.6	-19.0	-19.0	-19.0
Payments for acquisitions	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Financial investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Income from asset disposals	0.3	0.0	0.0	0.0	0.0	0.0	0.0
Net cash provided by investing activities [2]	-23.1	-20.1	-17.6	-15.5	-26.0	-26.0	-26.0
Change in financial liabilities	-6.9	4.5	4.5	4.5	-3.1	-2.0	-2.0
Dividends paid	-1.3	-2.6	-2.6	-0.8	-2.6	0.0	-3.2
Purchase of own shares	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital measures	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other	0.4	0.4	-2.6	-2.6	0.0	0.0	0.0
Net cash provided by financing activities [3]	-7.8	2.4	-0.7	1.1	-5.7	-2.0	-5.2
Change in liquid funds [1]+[2]+[3]	-13.4	0.8	3.9	6.8	-9.8	0.9	0.0
Effects of exchange-rate changes on cash	0.6	0.8	0.5	-1.4	0.0	0.0	0.0
Cash and cash equivalent at end of period	16.9	15.9	18.7	24.1	25.1	26.0	26.0

Financial Ratios


	2014	2015	2016	2017	2018e	2019e	2020e
Cash Flow							
FCF	-5.9	-1.5	4.6	5.7	-4.0	2.9	5.2
Free Cash Flow / Sales	-3.5 %	-0.8 %	0.1 %	2.8 %	-1.9 %	1.3 %	2.2 %
Free Cash Flow Potential	3.6	6.3	11.6	12.3	7.9	15.1	17.4
Free Cash Flow / Net Profit	-115.4 %	-43.7 %	2.7 %	122.7 %	-236.5 %	32.4 %	46.1 %
Interest Received / Avg. Cash	2.2 %	3.8 %	5.9 %	6.9 %	2.7 %	3.1 %	3.1 %
Interest Paid / Avg. Debt	7.5 %	6.6 %	4.2 %	4.7 %	1.4 %	1.5 %	1.6 %
Management of Funds							
Investment ratio	13.7 %	10.5 %	10.8 %	7.5 %	12.2 %	11.6 %	11.1 %
Maint. Capex / Sales	2.8 %	2.5 %	2.4 %	2.3 %	2.3 %	2.1 %	2.0 %
Capex / Dep	175.9 %	112.9 %	125.8 %	81.2 %	144.4 %	144.4 %	144.4 %
Avg. Working Capital / Sales	10.7 %	9.6 %	9.4 %	9.1 %	8.6 %	8.6 %	8.6 %
Trade Debtors / Trade Creditors	182.9 %	171.9 %	178.9 %	166.7 %	166.4 %	166.4 %	166.4 %
Inventory Turnover	8.2 x	7.8 x	8.6 x	9.7 x	9.5 x	9.2 x	9.2 x
Receivables collection period (days)	37	32	34	33	33	33	33
Payables payment period (days)	42	39	40	40	40	42	42
Cash conversion cycle (Days)	40	40	36	31	31	31	31

CAPEX and Cash Flow


in EUR m



Free Cash Flow Generation



Working Capital



Source: Warburg Research

Source: Warburg Research

Source: Warburg Research

LEGAL DISCLAIMER

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. All rights reserved.

COPYRIGHT NOTICE

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WHPG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Potential, Peer Group Comparison or Sum of the Parts Model (see also <http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation>). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).

SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.

Additional information for clients in the United States

1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.
2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934.
3. Any recipient of the Report should effect transactions in the securities discussed in the Report only through J.P.P. Euro-Securities, Inc., Delaware.
4. J.P.P. Euro-Securities, Inc. does not accept or receive any compensation of any kind for the dissemination of the research reports from Warburg.

Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

- 1- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a **share of more than 5%** of the equity capital of the analysed company.
- 2- Warburg Research, or an affiliated company, within the last twelve months participated in the **management of a consortium** for an issue in the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation.
- 3- Companies affiliated with Warburg Research **manage financial instruments**, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.
- 4- MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide **investment banking and/or investment services** and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation - provided that this disclosure does not result in the disclosure of confidential business information.
- 5- The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the investment recommendation** with the analysed company.
- 6- Companies affiliated with Warburg Research **regularly trade** financial instruments of the analysed company or derivatives of these.
- 6a- Warburg Research, or an affiliated company, holds a **net long position of more than 0.5%** of the total issued share capital of the analysed company.
- 6b- Warburg Research, or an affiliated company, holds a **net short position of more than 0.5%** of the total issued share capital of the analysed company.
- 6c- The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company.
- 7- The company preparing the analysis as well as its affiliated companies and employees have **other important interests** in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

This report has been made accessible to the company analysed.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)
Francotyp-Postalia	5, 6	http://www.mmwarburg.com/disclaimer/disclaimer_en/DE000FPH9000.htm

INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given price target in the opinion of the analyst who covers this financial instrument.

-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.
“-“	Rating suspended:	The available information currently does not permit an evaluation of the company.

WARBURG RESEARCH GMBH – ANALYSED RESEARCH UNIVERSE BY RATING


Rating	Number of stocks	% of Universe
Buy	126	62
Hold	68	33
Sell	3	1
Rating suspended	7	3
Total	204	100

WARBURG RESEARCH GMBH – ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	34	72
Hold	11	23
Sell	0	0
Rating suspended	2	4
Total	47	100

PRICE AND RATING HISTORY FRANCO-TYP-POSTALIA AS OF 16.11.2018



Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.

EQUITIES

Roland Rapelius +49 40 3282-2673
Head of Equities rrapelius@mmwarburg.com

RESEARCH

Michael Heider +49 40 309537-280
Head of Research mheider@warburg-research.com

Henner Rüschemeyer +49 40 309537-270
Head of Research hrueschmeier@warburg-research.com

Jonas Blum +40 40 309537-240
Small/Mid Cap Research jblum@warburg-research.com

Christian Cohrs +49 40 309537-175
Industrials & Transportation ccohrs@warburg-research.com

Felix Ellmann +49 40 309537-120
Software, IT fellmann@warburg-research.com

Jörg Philipp Frey +49 40 309537-258
Retail, Consumer Goods jfrey@warburg-research.com

Marius Fuhrberg +49 40 309537-185
Financial Services mfuhrberg@warburg-research.com

Ulrich Huwald +49 40 309537-255
Health Care, Pharma uhuwald@warburg-research.com

Thilo Kleibauer +49 40 309537-257
Retail, Consumer Goods tkleibauer@warburg-research.com

Eggert Kuls +49 40 309537-256
Engineering ekuls@warburg-research.com

Marina Manas Cháfer +49 40 309537-254
Renewables, Small/Mid Cap mmanaschafer@warburg-research.com

Andreas Pläsier +49 40 309537-246
Banks, Financial Services aplaesier@warburg-research.com

Jochen Reichert +49 40 309537-130
Telco, Internet, Media jreichert@warburg-research.com

J. Moritz Rieser +49 40 309537-260
Real Estate mrieser@warburg-research.com

Franz Schall +40 40 309537-230
Automobiles, Car Suppliers fschall@warburg-research.com

Malte Schaumann +49 40 309537-170
Technology mschaumann@warburg-research.com

Patrick Schmidt +49 40 309537-125
Leisure, Internet pschmidt@warburg-research.com

Oliver Schwarz +49 40 309537-250
Chemicals, Agriculture oschwarz@warburg-research.com

Cansu Tatar +49 40 309537-248
Cap. Goods ctatar@warburg-research.com

Marc-René Tonn +49 40 309537-259
Automobiles, Car Suppliers mtonn@warburg-research.com

Robert-Jan van der Horst +49 40 309537-290
Technology rvanderhorst@warburg-research.com

Andreas Wolf +49 40 309537-140
Software, IT awolf@warburg-research.com

INSTITUTIONAL EQUITY SALES

Klaus Schilling +49 40 3282-2664
Head of Equity Sales, Germany kschilling@mmwarburg.com

Tim Beckmann +49 40 3282-2665
United Kingdom tbeckmann@mmwarburg.com

Lyubka Bogdanova +49 69 5050-7411
United Kingdom, Australia lbogdanova@mmwarburg.com

Jens Buchmüller +49 69 5050-7415
Scandinavia, Austria jbuchmueller@mmwarburg.com

Alexander Eschweiler +49 40 3282-2669
Germany aeschweiler@mmwarburg.com

Matthias Fritsch +49 40 3282-2696
United Kingdom mfritsch@mmwarburg.com

Michael Kriszun +49 40 3282-2695
United Kingdom mkriszun@mmwarburg.com

Sanjay Oberoi +49 69 5050-7410
United Kingdom soberoi@mmwarburg.com

Simon Pallhuber +49 69 5050-7414
Switzerland, France spallhuber@mmwarburg.com

Angelika Flegler +49 69 5050-7417
Roadshow/Marketing aflegler@mmwarburg.com

Juliane Willenbruch +49 40 3282-2694
Roadshow/Marketing jwillenbruch@mmwarburg.com

SALES TRADING

Oliver Merckel +49 40 3282-2634
Head of Sales Trading omerckel@mmwarburg.com

Elyaz Dust +49 40 3282-2702
Sales Trading edust@mmwarburg.com

Michael Ilgenstein +49 40 3282-2700
Sales Trading milgenstein@mmwarburg.com

Bastian Quast +49 40 3282-2701
Sales Trading bquast@mmwarburg.com

Jörg Treptow +49 40 3282-2658
Sales Trading jtreptow@mmwarburg.com

Jan Walter +49 40 3282-2662
Sales Trading jwalter@mmwarburg.com

MACRO RESEARCH

Carsten Klude +49 40 3282-2572
Macro Research cklude@mmwarburg.com

Dr. Christian Jasperneite +49 40 3282-2439
Investment Strategy cjasperneite@mmwarburg.com

Our research can be found under:

Warburg Research research.mmwarburg.com/en/index.html

Bloomberg MMWA GO

FactSet www.factset.com

Thomson Reuters www.thomsonreuters.com

Capital IQ www.capitaliq.com

For access please contact:

Andrea Schaper +49 40 3282-2632
Sales Assistance aschaper@mmwarburg.com

Kerstin Muthig +49 40 3282-2703
Sales Assistance kmuthig@mmwarburg.com